Fund moves
12.9%Stake · was 12.9%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BRVE · NASDAQ · Pharmaceutical Preparations · No 10-K yet
Braveheart Bio (BRVE) · oqro.io/stocks/BRVE · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$20.39+1.12 (+5.81%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Braveheart Bio is on record in SEC filings since 2006.
No open-market sale by an insider of Braveheart Bio (BRVE) was filed with the SEC in the last 90 days.
No trade in Braveheart Bio (BRVE) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−31.6% (−$9.41) from Aug 6, 2026 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $29.80 on Aug 6, 2026 to $20.39 on Nov 20, 2026 (−31.6%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in San Francisco, CA. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
$1.69B
Short interest: 5.15M shares sold short (6.2% of shares outstanding), +5.1% vs the previous count, 19.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Braveheart Bio over the 12 months to Nov 18, 2026: 1 clinical trial.
Against the S&P 500 over the year
Since Aug 6, 2026, BRVE is down 31.6% and the index fund is down 10.2%: 21 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BRVE moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Revenue
—
Free cash flow, last 12 months
−$24.4M
This quarter −$24.4M, a year earlier −$740K
Net debt
—
Debt —, cash $121M, at Sep 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 10, 2026.
Forbion Growth Opportunities Fund III Cooperatief U.A.
13G · passive · Crossed 5% · 11.6M shares · filed Nov 16, 2026
Travis Murdoch
13G · passive · Crossed 5% · 8.38M shares · filed Nov 16, 2026
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
13G · passive · Crossed 5% · 7.42M shares · filed Nov 9, 2026
FMR LLC
13G · passive · Crossed 5% · 7.37M shares · filed Nov 5, 2026
Recent moves
Travis Murdoch went above 5%, with 9.3% · Schedule 13G, 2026
Forbion Growth Opportunities Fund III Cooperatief U.A. went above 5%, with 12.9% · Schedule 13G, 2026
Jiangsu Hengrui Pharmaceuticals Co., Ltd. went above 5%, with 8.2% · Schedule 13G, 2026
FMR LLC went above 5%, with 8.2% · Schedule 13G, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
1 active phase 3 trial and 0 active phase 2 trials led by this company, mostly in cardiomyopathy, hypertrophic obstructive. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Fails to deliver: 66K shares (about $1.34M) were not delivered on time for settlement on Oct 13, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 51.1% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (41.4% on ATS, 9.7% with other brokers), close to its 10-week average of 51.8%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INSTINCT X (12.8%), INTELLIGENT CROSS LLC (8.7%), SIGMA X2 (7.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.